Catalyst Pharmaceuticals, Inc.

337 articles with Catalyst Pharmaceuticals, Inc.

• Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

  3/15/2023

  Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today reported financial results for the fourth quarter and full year 2022 and provided a business update.

• Catalyst Pharmaceuticals Announces a Recent Third-Party Publication in Peer-Reviewed Journal Epilepsia Showing Perampanel (FYCOMPA®) Demonstrated High Efficacy in Patients with Rare Genetic Epilepsies

  3/8/2023

  Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced that an article was recently published in Epilepsia showed that perampanel reduces seizures with high effectivity in patients with rare genetic epileptic disease.

• Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 15, 2023

  3/1/2023

  Catalyst Pharmaceuticals, Inc. announced that it will release its fourth quarter and full-year 2022 financial results after the market close on Wednesday, March 15, 2023.

• Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 Total Revenues and Provides Full Year 2023 Revenue Guidance

  2/7/2023

  Catalyst Pharmaceuticals, Inc., today provided preliminary 2022 fourth quarter and full year total revenues estimates, a forecast of 2023 total revenue expectations, and a corporate update.

• Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII

  1/25/2023

  Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it has successfully completed the acquisition of the U.S. rights for FYCOMPA® (perampanel) CIII, from Eisai Co., Ltd, ("Eisai").

• Catalyst Pharmaceuticals Comments on FDA's Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra

  1/23/2023

  Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today commented on the FDA's notice setting forth its position on Orphan Drug Exclusivity in light of the 11th Circuit's decision in Catalyst Pharmaceuticals, Inc. v. Becerra.

• Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd

  12/19/2022

  Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX) today announced that it has entered into a definitive agreement with Eisai Co., Ltd, (“Eisai”) under which Catalyst will acquire the U.S. rights for FYCOMPA® (perampanel) CIII and an exclusive option period to review, evaluate and negotiate to acquire a rare epilepsy asset currently in Eisai’s pipeline.

• Catalyst Pharmaceuticals Reports Record Third Quarter 2022 Financial Results and Provides a Corporate Update

  11/9/2022

  Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today reported financial results and provided a corporate update for the third quarter of 2022.

• Catalyst Pharmaceuticals Named BioFlorida 2022 Company of the Year

  11/7/2022

  Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, announced that it has been named the “2022 David J. Gury Company of the Year” by BioFlorida.

• Catalyst Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 9, 2022

  10/25/2022

  Catalyst Pharmaceuticals, Inc. announced that it will release its third quarter 2022 financial results after market close on Wednesday, November 9, 2022.

• Catalyst Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

  9/9/2022

  Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that Patrick J. McEnany, Chairman and CEO of Catalyst, along with other members of the management team, will participate in the hybrid in-person and virtual H.C. Wainwright 24th Annual Global Investment Conference.

• Catalyst Pharmaceuticals To Participate in Citi's 17th Annual BioPharma Conference

  8/24/2022

  Catalyst Pharmaceuticals, Inc. today announced that Patrick J. McEnany, Chairman and CEO of Catalyst, along with other members of the management team, will participate at the upcoming Citi's 17th Annual BioPharma Conference.

• Catalyst Pharmaceuticals Delivers Strong Second Quarter 2022 Financial Results with Record FIRDAPSE® Revenues and Provides Corporate Update

  8/9/2022

  Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today reported financial results for the second quarter 2022 and provided a corporate update.

• Catalyst Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 9, 2022The Company Will Host a Conference Call and Webcast on August 10, 2022, at 8:30 AM ET

  7/26/2022

  Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it will release its second quarter 2022 financial results after market close on Tuesday, August 9, 2022.

• Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences - May 17, 2022

  5/17/2022

  Catalyst Pharmaceuticals, Inc. announced that Patrick J. McEnany, Chairman and CEO of Catalyst, along with other members of the management team, will participate at two upcoming conferences.

• Catalyst Pharmaceuticals Reports Record First Quarter 2022 Financial Results And Provides Corporate Update

  5/10/2022

  Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today reported financial results for the first quarter 2022 and provided a corporate update.

• Catalyst Pharmaceuticals to Report First Quarter 2022 Financial Results on May 10, 2022

  4/25/2022

  Catalyst Pharmaceuticals, Inc. announced that it will release its first-quarter 2022 financial results after market close on Tuesday, May 10, 2022.

• Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

  3/16/2022

  Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today reported financial results for the fourth quarter and full year 2021 and provided a corporate update.

• Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce a Second Favorable Canadian Federal Court Ruling Setting Aside Approval of Ruzurgi®

  3/11/2022

  Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX),  and KYE Pharmaceuticals Inc. ("KYE"), today announced receipt of a favorable decision from the Federal Court of Canada (“Court”) setting aside for the second time the decision of Canada’s national healthcare regulatory agency, Health Canada, to approve Ruzurgi® (amifampridine) for Lambert-Eaton Myasthenic Syndrome ("LEMS") patients.

• Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 16, 2022The Company Will Host a Conference Call and Webcast on March 17, 2022, at 8:30 AM ET

  3/3/2022

  Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that it will release its fourth quarter and full-year 2021 financial results after market close on Wednesday, March 16, 2022.